文献速递糖尿病

1型糖尿病临床试验中不同血糖类别下A1C与GMI的变化比较

Changes in A1C Versus GMI Across Glycemic Categories in Clinical Trials of Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究利用DCLP3、DCLP5和WISDM三项1型糖尿病临床试验数据,比较干预3个月后中央实验室检测的A1C与由传感器葡萄糖估算的GMI在变化幅度和方向上的差异。结果显示A1C与GMI变化仅呈中等相关(r=0.34),基线A1C>9%和7%-9%者A1C下降幅度均大于GMI,基线A1C<7%者无显著差异,提示GMI可能低估A1C的真实变化。

要点

  • A1C与GMI变化呈中等相关(r=0.34)。
  • 基线A1C>9%者A1C降幅大于GMI降幅(P<.01)。
  • 基线A1C 7%-9%者A1C降幅亦大于GMI(P<.01)。

核心结论

  • GMI的变化受参与者基线A1C影响,且低估A1C的真实变化;在1型糖尿病临床试验或真实世界研究中将GMI作为终点可能无法可靠反映干预疗效。

研究设计与样本

  • 从DCLP3、DCLP5和WISDM三项1型糖尿病临床试验中收集基线和3个月时中央实验室检测的A1C及由传感器葡萄糖估算的GMI,纳入儿童、青少年、成人及老年人。

主要发现

  • A1C与GMI变化之间呈中等相关(r=0.34)。
  • 基线A1C>9%者A1C降幅为-1.2(-2.1至-0.6),GMI降幅为-0.6(-0.94至0),P<.01。
  • 基线A1C在7%-9%者A1C降幅为-0.4(-0.9至-0.1),GMI降幅为-0.12(-0.49至0.21),P<.01。
  • 基线A1C<7%者A1C与GMI变化无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The glucose management indicator (GMI) is an estimated glycated hemoglobin (A1C) derived from sensor glucose. Though it is being used to approximate A1C in clinical trials, there are no data on direction and magnitude of change in GMI vs A1C after an intervention. OBJECTIVE: To evaluate the magnitude and direction of changes in A1C compared to GMI across different baseline glycemic categories in type 1 diabetes (T1D) clinical trials. METHODS: Baseline and 3-month central laboratory-measured A1C and estimated GMI from sensor glucose were collected from T1D clinical trials (DCLP3, DCLP5, and WISDM), encompassing children, adolescents, adults, and older adults. Magnitude and direction of changes (baseline-3 months) in A1C vs GMI were compared overall across the studies and by stratified baseline A1C (<7%, 7%-9%, >9%). RESULTS: A modest correlation was found between changes in A1C and GMI (r = 0.34). Participants with baseline A1C > 9% had larger reductions in A1C compared to GMI (-1.2 [-2.1 to -0.6] vs -0.6 [-0.94 to 0], P < .01). Those with baseline A1C between 7% and 9% showed a greater decline in A1C than GMI (-0.4 [-0.9 to -0.1] vs -0.12 [-0.49 to 0.21], P < .01). No significant difference was observed for baseline A1C < 7%. CONCLUSION: Change in GMI is influenced by the baseline A1C of the participants and it underestimates the true change in A1C. Use of GMI as an endpoint in clinical trials may not reliably capture efficacy of an intervention in T1D trials or real-world studies.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Montaser E, Abad SE, Shah VN, et al. Changes in A1C Versus GMI Across Glycemic Categories in Clinical Trials of Type 1 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 40170496. doi:10.1210/clinem/dgaf211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。